cisplatin,pembrolizumab,enfortumab vedotin,atezolizumab,nivolumab,ipilimumab
astellas,merck,bms,seagen,roche
['vedo', 'methotrexate', 'pembro', 'atezo', ' vedo', 'cisplatin', 'sacituzumab', 'urothelial', 'key,note,361', 'key,note,52', 'urothelial carcinoma', 'key,note,57', ' cis ', 'imvigor130', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'carboplatin', 'ev-103', 'check,mate,901', 'doxorubicin', 'gemcitabine', ' uc,(-ucsd),(-ucsf),']
#gu23
always a treat to hear she shares her insights
- chemo + io did not work with atezo or pembro in muc
- cis may be better than carbo (need more data)
- careful with deriving conclusions from subsequent study arms if the first questions asked are negative 
GU Oncologist/Clinical Trials/ Experimental Therapeutics @UCD_Cancer @UCDavisHealth via @uofcincy @GoBEARCATS. Tweets= My opinions #RCC #ASCO #immunotherapy